New hope for Tough-to-Treat lymphoma: adding drug to standard chemotherapy
NCT ID NCT07348575
Summary
This study is testing whether adding a drug called decitabine to standard chemotherapy (R-CHOP) works better for treating a specific type of lymphoma linked to the Epstein-Barr virus (EBV). It will involve 80 adults newly diagnosed with this cancer who have not had prior treatment. Researchers will compare the two-drug combination against standard chemotherapy alone to see which helps patients live longer without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, LARGE-CELL, DIFFUSE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330000, China
Conditions
Explore the condition pages connected to this study.